In Vivo CRISPR Therapy: From Sickle Cell Cure to the Future of Genetic Medicine

In November 2023, the FDA and the UK's MHRA approved the world's first CRISPR-based therapy for sickle cell disease. It was called Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and it worked by editing a patient's own stem cells outside the body before returning them.

That approach — *ex vivo* editing — was an engineering marvel. But it was also, in some ways, a workaround. The patient's stem cells had to be extracted, edited in a laboratory, then reinfused. The process takes months, costs over two million dollars per treatment, and requires specialized infrastructure that doesn't exist in most of the world.

Here's the question that's driving the next generation of gene medicine: what if you could skip all of that and edit cells directly inside the body?

## What "In Vivo" Actually Means

*In vivo* means "in the living" — performing the genetic edit inside the patient's body rather than in a laboratory dish. The concept sounds straightforward. In practice, it requires solving three simultaneous engineering problems that took decades of molecular biology to address.

**Problem one: delivery.** CRISPR needs to reach the right cells. If you want to edit liver cells, your delivery vehicle needs to navigate the bloodstream, pass through the liver's fenestrated capillaries, enter hepatocytes without triggering an immune response, and release its cargo at the right time. The dominant solution today is lipid nanoparticles (LNPs) — tiny fat bubbles that encapsulate the CRISPR components and can be tuned to preferentially accumulate in specific tissues.

**Problem two: specificity.** Your guide RNA needs to find exactly the right DNA sequence among the three billion base pairs in each cell's nucleus. Off-target edits — cuts at unintended sites — can cause deletions, insertions, or chromosomal rearrangements. Newer CRISPR variants like base editors and prime editors make single-letter changes without cutting the DNA double strand, dramatically reducing off-target risk.

**Problem three: immune response.** The components of CRISPR — particularly the Cas9 protein derived from bacteria — can trigger immune reactions. Humans have often been exposed to *Staphylococcus aureus* and other Cas9-bearing bacteria, and many carry pre-existing antibodies that can neutralize the editing machinery before it reaches its target.

> 🔬 **Quick experiment:** Take a drop of blood from a donor who has previously had a strep throat infection, and test it for antibodies against *S. pyogenes* Cas9. Odds are roughly 58 percent that they'll test positive — meaning standard Cas9 would face immune neutralization before it could edit anything.

## What's Actually Working in 2026

The most striking clinical success story is **transthyretin amyloidosis** (ATTR), a progressive disease caused by a misfolded protein produced by the liver that deposits in the heart and nerves. In 2022, Intellia Therapeutics published Phase 1 data showing that a single intravenous injection of LNP-encapsulated CRISPR machinery reduced transthyretin protein levels by 87 percent — and the reduction appeared durable at 12 months of follow-up. A single injection, one time.

By 2026, the Phase 3 trial data has confirmed these results. The liver turns out to be an ideal target for in vivo delivery precisely because LNPs naturally accumulate there. NTLA-2001, Intellia's lead ATTR program, is likely to be one of the first in vivo CRISPR therapies to reach full regulatory approval.

Beyond ATTR, the field has expanded rapidly. **Hemophilia A and B**, where the missing clotting factor gene can be delivered to liver cells, represent one of the largest unmet needs. **Hypercholesterolemia** — specifically the rare but severe form caused by PCSK9 mutations — is being targeted by base-editing approaches that permanently silence the gene, potentially replacing a lifetime of injections with a single treatment.

The more ambitious programs are targeting tissues that LNPs don't naturally reach. Editing **muscle cells** for Duchenne muscular dystrophy requires either engineered viral vectors (AAVs) or novel delivery methods. **Lung cells** for cystic fibrosis present a different delivery challenge — aerosol inhalation can bring CRISPR to airway cells, but achieving efficient editing in the cells that matter most (basal cells, the stem-like progenitors of the airway epithelium) remains difficult.

## What We Still Don't Know

The durability question is genuinely open. Dividing cells dilute their edited gene copies with each division. In non-dividing tissues like liver and neurons, edits appear to be permanent. In stem cell populations — bone marrow, for instance — edited cells need to outcompete unedited ones to provide lasting benefit.

There is also a deeper question about what happens when CRISPR scales from rare diseases to common ones. The technology economics today make treatments prohibitively expensive. But the manufacturing processes are improving rapidly. The question of whether in vivo CRISPR can become a genuinely mass-market medical tool — the way vaccines are — is not yet answered. The biology suggests it might. The economics are still being written.

In Vivo CRISPR Therapy: From Sickle Cell Cure to the Future of Genetic Medicine

// COMMENTS

ON THIS PAGE